The US FDA’s newest expedited review program, the regenerative medicine advanced therapy (RMAT) designation, is gaining momentum after a slower ramp-up than the agency’s older breakthrough therapy designation (BTD), the Pink Sheet US FDA Performance Tracker shows.
Key Takeaways
-
2024 is shaping up to be a banner year for the US FDA’s regenerative medicine advanced therapy designation with totals already exceeding the previous annual record for designations by more than one-third.
-
Only 15% of novel biologics approved by CBER have held an RMAT designation since the program was enacted in late 2016, but recipients make up 60% of 2024 novel approvals so far
The FDA’s Center for Biologics Evaluation and Research has approved 11 novel biologics with an RMAT, starting with Bristol Myers Squibb Company’s Breyanzi (lisocabtagene maraleucel), approved 5 February 2021 for a third-line and later large B-cell lymphoma indication
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?